Bosh sahifaN1BI34 • BVMF
add
Neurocrine Biosciences Bdr
Yopilish kursi
34,07 R$
Yillik diapazon
25,64 R$ - 44,18 R$
Bozor kapitalizatsiyasi
12,91 mlrd USD
Oʻrtacha hajm
182,00
Narx/foyda
-
Dividend daromadliligi
-
Yangiliklarda
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (USD) | dek, 2025info | Y/Y qiyosi |
|---|---|---|
Daromad | 805,50 mln | 28,33% |
Joriy xarajat | 302,50 mln | 5,11% |
Sof foyda | 153,70 mln | 49,08% |
Sof foyda marjasi | 19,08 | 16,13% |
Har bir ulushga tushum | 1,88 | 11,24% |
EBITDA | 234,70 mln | 54,31% |
Amaldagi soliq stavkasi | 35,80% | — |
Balans
Jami aktivlari
Jami passivlari
| (USD) | dek, 2025info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 1,48 mlrd | 37,57% |
Jami aktivlari | 4,63 mlrd | 24,55% |
Jami passivlari | 1,38 mlrd | 22,09% |
Umumiy kapital | 3,25 mlrd | — |
Tarqatilgan aksiyalar | 100,36 mln | — |
Narxi/balansdagi bahosi | 1,05 | — |
Aktivlardan daromad | 12,77% | — |
Kapitaldan daromad | 15,76% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (USD) | dek, 2025info | Y/Y qiyosi |
|---|---|---|
Sof foyda | 153,70 mln | 49,08% |
Operatsiyalardan naqd pul | 388,40 mln | 60,16% |
Sarmoyadan naqd pul | -52,90 mln | 22,55% |
Moliyadan naqd pul | 37,30 mln | 112,86% |
Naqd pulning sof oʻzgarishi | 372,80 mln | 421,10% |
Boʻsh pul | 312,50 mln | 15,90% |
Haqida
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine was approved in the US to treat adults with tardive dyskinesia.
The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids. Wikipedia
Tashkil etilgan
1992
Sayt
Xodimlar soni
2 000
